Uromitexan

PreclinicalSmall molecule

CCuracell Holding AB

Uromitexan is one of 30 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerRecruiting

Metastatic Colorectal CancerPreclinical

Recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 3

45 2

Braftovi

Pfizer

Phase 3

11 3

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

2 4

Fusilev

DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)

Phase 3

1 5

Cosela

PPharmacosmos A/S

Phase 3

1 6

Vatalanib

Novartis

Phase 3

2 7

PF-08634404

Pfizer

Phase 3

—8

Brivanib Alaninate

GGynecologic Oncology Group

Phase 3

1 9

FOLFOX 2d

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 10

Napabucasin

Sumitomo Pharma America, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Metastatic Colorectal Cancer

NCT07255664

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

A FIH, Phase I/IIa, Open-label Trial Assessing Safety, Tolerability, and Feasibility of Repeated Administrations of a Novel Autologous TIL-based Immunotherapy in Patients With Metastatic Colorectal or Prostate Cancer

Recruiting·CCuracell Holding AB·Preclinical·NCT07255664·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Uromitexan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Uromitexan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Uromitexan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Curacell Holding AB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCuracell Holding AB

Uromitexan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News